Stomach Cancer clinical trials in South Dakota

8 actively recruiting stomach cancer trials at 6 sites across South Dakota.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05677490

Sites in South Dakota:

Avera Cancer Institute-Aberdeen — Aberdeen, South Dakota
Avera Cancer Institute - Mitchell — Mitchell, South Dakota
Avera Cancer Institute at Pierre — Pierre, South Dakota
Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting NIH

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06203600

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca

NCT ID: NCT07431281

Sites in South Dakota:

Research Site — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim

NCT ID: NCT06324357

Sites in South Dakota:

Avera Cancer Institute — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

NCT ID: NCT04389632

Sites in South Dakota:

Sanford Cancer Center — Sioux Falls, South Dakota
Sanford Research — Sioux Falls, South Dakota
Sanford USD Medical Center — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501…

Sponsor: BeiGene

NCT ID: NCT06257264

Sites in South Dakota:

Avera Cancer Institute — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in South Dakota:

Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT07283939

Sites in South Dakota:

Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20